Overview

Albumin Administration and Outcomes in Cardiac Surgery

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The invesitgators utilized the Cerner HealthFacts database (a large HIPAA-compliant clinical-administrative database maintained by Cerner Inc., USA) to identify a cohort of 6,249 adults that underwent on-pump cardiac surgery for valve and/or coronary artery procedures between January 2001 and March 2013. Of these, the investigators selected 1136 patients who received 5% albumin on the day of or the day following cardiac surgery and matched them (1:1) with 1136 patients who did not receive albumin. Characteristics on which patients were matched included patient demographic, hospital and procedural characteristics, baseline patient comorbidities including preoperative CKD and 26 other grouped conditions, as well as acute severity of illness at admission to ICU.
Details
Lead Sponsor:
Vanderbilt University
Collaborators:
Duke University
Grifols Biologicals Inc.
Grifols Biologicals, LLC
Treatments:
Plasma-lyte 148